Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Market Crashes, India’s Wockhardt Is Pushed To Consider Equity Dilution To Raise Funds To Repay Debts

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A headlong fall in market valuation of large Indian drug makers over the last year is pushing their promoters to consider equity stake dilutions to repay debts or honor similar commitments. India's sixth-largest drug maker Wockhardt may see its promoter Habil Khorakiwala dilute 10 to 15 percent of his and his family's 74 percent equity in favor of private-equity players to raise about $150 million, PharmaAsia News has learned

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts